NASDAQ
SWTX

SpringWorks Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

SpringWorks Therapeutics Inc Stock Price

Vitals

Today's Low:
$26.6
Today's High:
$27.28
Open Price:
$27.05
52W Low:
$21.04
52W High:
$34.16
Prev. Close:
$27.21
Volume:
414370

Company Statistics

Market Cap.:
$1.70 billion
Book Value:
7.232
Revenue TTM:
$35 million
Operating Margin TTM:
0%
Gross Profit TTM:
$35 million
Profit Margin:
0%
Return on Assets TTM:
-43.98%
Return on Equity TTM:
-76.67%

Company Profile

SpringWorks Therapeutics Inc had its IPO on 1987-06-05 under the ticker symbol SWTX.

The company operates in the Healthcare sector and Biotechnology industry. SpringWorks Therapeutics Inc has a staff strength of 227 employees.

Stock update

Shares of SpringWorks Therapeutics Inc opened at $27.05 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $26.6 - $27.28, and closed at $26.73.

This is a -1.76% slip from the previous day's closing price.

A total volume of 414,370 shares were traded at the close of the day’s session.

In the last one week, shares of SpringWorks Therapeutics Inc have slipped by -11.87%.

SpringWorks Therapeutics Inc's Key Ratios

SpringWorks Therapeutics Inc has a market cap of $1.70 billion, indicating a price to book ratio of 2.4437 and a price to sales ratio of 74.496.

In the last 12-months SpringWorks Therapeutics Inc’s revenue was $35 million with a gross profit of $35 million and an EBITDA of $-309643008. The EBITDA ratio measures SpringWorks Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, SpringWorks Therapeutics Inc’s operating margin was 0% while its return on assets stood at -43.98% with a return of equity of -76.67%.

In Q2, SpringWorks Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

SpringWorks Therapeutics Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-4.94 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into SpringWorks Therapeutics Inc’s profitability.

SpringWorks Therapeutics Inc stock is trading at a EV to sales ratio of 64.1764 and a EV to EBITDA ratio of -3.3041. Its price to sales ratio in the trailing 12-months stood at 74.496.

SpringWorks Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$517.33 million
Total Liabilities
$41.91 million
Operating Cash Flow
$0
Capital Expenditure
$3.09 million
Dividend Payout Ratio
0%

SpringWorks Therapeutics Inc ended 2024 with $517.33 million in total assets and $0 in total liabilities. Its intangible assets were valued at $517.33 million while shareholder equity stood at $451.44 million.

SpringWorks Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $41.91 million in other current liabilities, 6000.00 in common stock, $-721275000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $115.00 million and cash and short-term investments were $476.71 million. The company’s total short-term debt was $811,000 while long-term debt stood at $0.

SpringWorks Therapeutics Inc’s total current assets stands at $483.90 million while long-term investments were $4.81 million and short-term investments were $361.71 million. Its net receivables were $0 compared to accounts payable of $3.45 million and inventory worth $0.

In 2024, SpringWorks Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $3.09 million.

Comparatively, SpringWorks Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$26.73
52-Week High
$34.16
52-Week Low
$21.04
Analyst Target Price
$50.17

SpringWorks Therapeutics Inc stock is currently trading at $26.73 per share. It touched a 52-week high of $34.16 and a 52-week low of $34.16. Analysts tracking the stock have a 12-month average target price of $50.17.

Its 50-day moving average was $28.02 and 200-day moving average was $27.3 The short ratio stood at 32.76 indicating a short percent outstanding of 0%.

Around 660.6% of the company’s stock are held by insiders while 11034.2% are held by institutions.

Frequently Asked Questions About SpringWorks Therapeutics Inc

The stock symbol (also called stock or share ticker) of SpringWorks Therapeutics Inc is SWTX

The IPO of SpringWorks Therapeutics Inc took place on 1987-06-05

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$124.28
1.94
+1.59%
$0.12
-0
-0.08%
$0.78
0.01
+1.3%
$109.2
-7.1
-6.1%
$3.11
-0.13
-4.01%
Novan Inc (NOVN)
$0.02
0
+19.5%
KAPIL COTEX LTD. (KAPILCO)
$115.4
2.25
+1.99%
$1.01
0
0%
$42.32
-1.68
-3.82%
$136.9
-9.2
-6.3%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

Address

100 Washington Boulevard, Stamford, CT, United States, 06902